United States
Revenue Exposure
North America (nearly all Dx in the US) accounts for 87% of total revenues; Dx revenues were generated almost entirely in the US.
Relevance 90·Dependency 80·Confidence 95
Source evidence
“Nearly all of Dx’s revenues were generated in the U.S.”
MCOs and health insurance payers
Customer Exposure
Diagnostics testing is billed primarily to third-party payers; payer mix shift and reimbursement pressure affect revenue.
Relevance 85·Dependency 80·Confidence 93
Source evidence
“The Company's diagnostic testing services are primarily billed to third parties, including MCOs, employer plans, and other health insurance providers”
Third Party (health plans, MCOs, employer plans)
Revenue Exposure
Third-party payers are the largest Dx payer group at 37% of total revenues.
Relevance 85·Dependency 75·Confidence 95
Source evidence
“Third party37 %— %— %37 %”
Pharmaceutical, biotechnology, and medical device companies
Customer Exposure
BLS revenue depends on pharma/biotech/medtech R&D spending; regulatory changes or cost-control could reduce demand.
Relevance 85·Dependency 75·Confidence 92
Source evidence
“efforts to control drug and device costs, or changes in insurer reimbursement practices, may lead customers to reduce R&D spending, which could adversely affect BLS's business”
Pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs
Revenue Exposure
Biopharma customers generate 22% of total revenue, all within BLS, spanning North America 9%, Europe 9%, and other regions 4%.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“Pharmaceutical, biotechnology, medical device, and diagnostic companies, and CROs9 %9 %4 %22 %”
OBBBA changes to Medicaid and ACA could reduce insurance coverage and diagnostics testing utilization.
Relevance 85·Dependency 60·Confidence 93
Source evidence
“changes to Medicaid and the ACA, and could lead to revised regulatory requirements and reduced federal funding”
U.S. Protecting Access to Medicare Act (PAMA)
Regulatory Exposure
PAMA-driven changes to reimbursement/coverage for laboratory testing are a leading disclosed risk to revenue.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of PAMA”
PAMA reduces Medicare reimbursement for tests, a direct pricing headwind for Dx.
Relevance 80·Dependency 55·Confidence 95
Source evidence
“PAMA has already reduced Medicare reimbursement rates for many tests, and further reductions are expected”
U.S. Clinical Laboratory Improvement Amendments (CLIA)
Regulatory Exposure
Loss or suspension of licenses under CLIA or Medicare/Medicaid could impair laboratory operations.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of laws or regulations of CLIA, Medicare, Medicaid”
Managed care organizations (MCOs)
Customer Exposure
Failure to retain MCO business due to strategy or business model changes is a disclosed risk; payer mix shifts affect reimbursement.
Relevance 75·Dependency 60·Confidence 85
Source evidence
“failure to retain or attract business from MCOs as a result of changes in strategy or business models”
Reagents, test kits, and laboratory instruments
Supplier Dependency
Manufacturers' discontinuations or recalls of reagents, test kits, or instruments could impact costs, testing volume, and revenue.
Relevance 70·Dependency 75·Confidence 93
Source evidence
“manufacturers discontinue or recall reagents, test kits, or instruments used by the Company to perform laboratory testing”
Medicare/Medicaid federal healthcare programs
Revenue Exposure
Medicare/Medicaid represents 8% of total revenues, creating government reimbursement and regulatory exposure.
Relevance 70·Dependency 45·Confidence 92
Source evidence
“Medicare and Medicaid8 %— %— %8 %”
Skilled labor competition
Cost Driver
Competition for qualified lab and patient-facing personnel and wage growth could raise costs and disrupt operations.
Relevance 65·Dependency 55·Confidence 90
Source evidence
“as a result of increased competition for talent, wage growth, or other market factors, could lead to strategic and operational challenges”
Patient payment responsibility / consumer-driven health plans
Revenue Exposure
Shift to consumer-driven health plans with higher member cost-sharing increases patient responsibility, pressuring cash collections and DSO.
Relevance 65·Dependency 55·Confidence 85
Source evidence
“the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing”
Third-party suppliers and vendors
Supplier Dependency
Changes or disruption in services or supplies provided by third parties, or their termination, could disrupt operations; vendor performance is monitored via quality programs.
Relevance 60·Dependency 55·Confidence 85
Source evidence
“changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company's performance standards and requirements”
Wage growth and competition for talent are disclosed factors affecting ability to attract and retain qualified personnel.
Relevance 60·Dependency 50·Confidence 85
Source evidence
“due to increased competition for talent, wage growth, or other market factors beyond the Company's control”
2025 minority-stake investment in SYNLAB supports Labcorp's international specialty diagnostics and CDx expansion strategy.
Relevance 60·Dependency 25·Confidence 90
Source evidence
“During 2025, the Company advanced its international strategy through the acquisition of a minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe.”
Artificial intelligence / machine learning
Technology Dependency
Adverse effects from use of or regulation of AI and machine learning tools are disclosed risks to operations.
Relevance 55·Dependency 40·Confidence 80
Source evidence
“or adverse effects from the use of or regulation of AI and machine learning tools”
Geopolitical events and public health crises
Geopolitical Exposure
Natural disasters, adverse weather, geopolitical events, and public health crises could cause business interruption, supply chain disruption, and higher costs.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in material cost or other operating costs, or other impacts on the business due to natural disasters; adverse weather; geopolitical events; public health crises”
Europe contributes 9% of total revenues and 41% of BLS revenues are international, driving FX translation exposure; 2025 FX translation adjustments were +$231.7M.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“Foreign currency translation adjustments231.7 (217.1)183.1”
Artificial intelligence
Competitive Exposure
AI applied to testing could reduce demand for Labcorp's services or benefit competitors faster.
Relevance 55·Dependency 30·Confidence 90
Source evidence
“application of AI to testing could reduce demand for the Company's services, or competitors could adopt use of these technologies”